Soll Dominik, Gawron Julia, Pletsch-Borba Laura, Spranger Joachim, Mai Knut
Department of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Chariteplatz 1, 10117, Berlin, Germany.
NutriAct-Competence Cluster Nutrition Research Berlin-Potsdam, Nuthetal, Germany.
Nutr Metab (Lond). 2022 Mar 28;19(1):25. doi: 10.1186/s12986-022-00660-w.
While short-term effects of weight loss on quality of life and metabolic aspects appear to be different in metabolically healthy (MHO) and metabolically unhealthy obese (MUO), respective long-term data is still missing. Given the high relevance of long-term changes, we aimed to address these in this post-hoc analysis of the MAINTAIN trial.
We analyzed 143 overweight/obese subjects (BMI ≥ 27 kg/m, age ≥ 18 years) before and after a 3-month weight loss program (≥ 8% weight loss), after a 12-month period of a randomized weight maintenance intervention (n = 121), and after another 6 months without intervention (n = 112). Subjects were retrospectively grouped into MHO and MUO by the presence of metabolic syndrome and secondarily by estimates of insulin sensitivity (HOMA-IR and ISI). Quality of life (QoL), blood pressure, lipids, HOMA-IR, and ISI were assessed and evaluated using mixed model analyses.
Despite similar short- and long-term weight loss, weight loss-induced improvement of HOMA-IR was more pronounced in MUO than MHO after 3 months (MHO: 2.4[95%-CI: 1.9-2.9] vs. 1.6[1.1-2.1], p = 0.004; MUO: 3.6[3.2-4.0] vs. 2.0[1.6-2.4], p < 0.001; p = 0.03 for inter-group comparison). After 21 months, the beneficial effect was no longer seen in MHO (2.0[1.5-2.6], p = 1.0), while it remained partially preserved in MUO (2.9[2.4-3.3], p = 0.002). QueryShort-term improvements of lipid parameters were similar in both groups. However, long-term improvements of HDL-cholesterol and triglycerides were only seen in MUO (44.4[41.5-47.4] vs. 49.3[46.2, 52.3] mg/dl, p < 0.001; 176.8[158.9-194.8] vs. 138.8[119.4-158.3] mg/dl, p < 0.001, respectively) but not in MHO. Weight loss-induced improvements in the QoL and particularly the physical health status were maintained in MUO until the end of the trial, while benefits disappeared over time in MHO. Group allocation by HOMA-IR and ISI revealed higher benefits for MUO mainly in parameters of the glucose metabolism and QoL.
Our data demonstrates stronger and longer-lasting improvements of metabolism and QoL in MUO after weight loss. Trial registration (ClinicalTrials.gov): NCT00850629. Registered 25 February 2009, https://clinicaltrials.gov/ct2/show/NCT00850629 .
虽然体重减轻对代谢健康(MHO)和代谢不健康肥胖(MUO)人群生活质量和代谢方面的短期影响似乎有所不同,但各自的长期数据仍然缺失。鉴于长期变化的高度相关性,我们旨在通过对MAINTAIN试验的事后分析来解决这些问题。
我们分析了143名超重/肥胖受试者(BMI≥27kg/m²,年龄≥18岁),这些受试者在为期3个月的体重减轻计划(体重减轻≥8%)前后、为期12个月的随机体重维持干预后(n = 121)以及在无干预的另外6个月后(n = 112)的情况。根据代谢综合征的存在情况,并其次根据胰岛素敏感性估计值(HOMA-IR和ISI),将受试者回顾性地分为MHO和MUO组。使用混合模型分析评估和评价生活质量(QoL)、血压、血脂、HOMA-IR和ISI。
尽管短期和长期体重减轻情况相似,但在3个月后,体重减轻引起的HOMA-IR改善在MUO组比MHO组更明显(MHO组:2.4[95%置信区间:1.9 - 2.9]对1.6[1.1 - 2.1],p = 0.004;MUO组:3.6[3.2 - 4.0]对2.0[1.6 - 2.4],p < 0.001;组间比较p = 0.03)。21个月后,MHO组不再有有益效果(2.0[1.5 - 2.6],p = 1.0),而MUO组仍部分保留(2.9[2.4 - 3.3],p = 0.002)。两组脂质参数的短期改善相似。然而,HDL胆固醇和甘油三酯的长期改善仅在MUO组中可见(分别为44.4[41.5 - 47.4]对49.3[46.2, 52.3]mg/dl,p < 0.001;176.8[158.9 - 194.8]对138.8[119.4 - 158.3]mg/dl,p < 0.001),而MHO组未出现。体重减轻引起的QoL改善,特别是身体健康状况的改善,在MUO组中一直维持到试验结束,而MHO组的益处随时间消失。根据HOMA-IR和ISI进行分组显示,MUO组主要在葡萄糖代谢参数和QoL方面获益更大。
我们的数据表明,MUO组在体重减轻后代谢和QoL的改善更强且更持久。试验注册(ClinicalTrials.gov):NCT00850629。于2009年2月25日注册,https://clinicaltrials.gov/ct2/show/NCT00850629 。